Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
November 08 2022 - 4:05PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced today
that the Company will host a conference call on Wednesday, November
9, 2022 at 8:30 a.m. Eastern Time to report results from its OASIS
Phase 1/2a clinical trial of CLS-AX (axitinib injectable
suspension) in neovascular age-related macular degeneration (wet
AMD) patients. As previously announced, on November 9, 2022,
Clearside will also report its financial results for the quarter
ended September 30, 2022.
The live and archived webcast may be accessed on
the Clearside website under the Investors section: Events and
Presentations. The live call can be accessed by dialing (888)
506-0062 (domestic) or (973) 528-0011 (international) and entering
conference code: 111701. An archive of the webcast will be
available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
proprietary SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector and strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. Clearside’s first product, XIPERE®
(triamcinolone acetonide injectable suspension) for suprachoroidal
use, is commercially available in the U.S. For more information,
please visit www.clearsidebio.com.
Investor and Media Contact:
Jenny Kobin Remy Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2023 to Apr 2024